- Home
- Publications
- Publication Search
- Publication Details
Title
MUC1 immunotherapy is here to stay
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 13, Issue 1, Pages 35-49
Publisher
Informa Healthcare
Online
2012-09-24
DOI
10.1517/14712598.2012.725719
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cytotoxic T-lymphocyte Immunotherapy for Ovarian Cancer
- (2012) Stephen E. Wright et al. JOURNAL OF IMMUNOTHERAPY
- Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
- (2011) N. K. Ibrahim et al. CLINICAL CANCER RESEARCH
- Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
- (2011) S. A. Gulec et al. CLINICAL CANCER RESEARCH
- MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine Promoters
- (2011) Sandra Cascio et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
- (2011) Charles Butts et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies
- (2010) S. P. Pinheiro et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
- (2010) Stéphane Oudard et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
- (2010) Jürgen Kuball et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer
- (2010) Charles Butts et al. Clinical Lung Cancer
- A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
- (2010) Rodryg Ramlau et al. Journal of Thoracic Oncology
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
- (2010) Susanne M Rittig et al. MOLECULAR THERAPY
- MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition
- (2010) L D Roy et al. ONCOGENE
- MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor- B p65 Transcription Factor
- (2009) R. Ahmad et al. CANCER RESEARCH
- Tumor Burden Influences Cytotoxic T Cell Development in Metastatic Breast Cancer Patients—A Phase I/II Study
- (2009) Stephen E. Wright et al. IMMUNOLOGICAL INVESTIGATIONS
- Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer
- (2009) Ann Willman Silk et al. MOLECULAR IMMUNOLOGY
- Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer
- (2009) N Khodarev et al. ONCOGENE
- Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
- (2008) J. L. Gulley et al. CLINICAL CANCER RESEARCH
- Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
- (2008) Angèle L.M. Oei et al. INTERNATIONAL JOURNAL OF CANCER
- Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti‐MUC1 antibody immune selection
- (2008) Juan Carlos Varela et al. INTERNATIONAL JOURNAL OF CANCER
- MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
- (2008) R. Dreicer et al. INVESTIGATIONAL NEW DRUGS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now